☆ 4.7 Article

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021

ANNALS OF INTERNAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Review Medical Laboratory Technology

Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT)

Emmanuel J. Favaloro et al.

Summary: COVID-19 vaccines may cause adverse events, and one rare event called vaccine-induced (immune) thrombotic thrombocytopenia (VITT) can have serious consequences. In response to increasing reports of VITT, expert groups have formulated guidelines for diagnosis and management.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)

Add to Collection

Article Hematology

Vaccine-induced immune thrombotic thrombocytopenia

Frederikus A. Klok et al.

Summary: In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were rapidly developed and introduced, leading to a major impact on the evolution of the disease. However, reports of rare side-effects such as vaccine-induced immune thrombotic thrombocytopenia (VITT) have emerged, requiring prompt testing and treatment with intravenous immunoglobulin and non-heparin anticoagulants.

LANCET HAEMATOLOGY (2022)

Add to Collection

Review Immunology

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Jerome Custers et al.

Summary: This article reviews the safety and efficacy of Ad26 vector-based vaccines in clinical trials, showing good tolerability and immunogenicity in multiple studies. New developments in Ad26-based vaccines, including a COVID-19 vaccine currently in phase 3 clinical evaluation, are promising for vaccine development.

VACCINE (2021)

Add to Collection

Article Hematology

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede et al.

Summary: This study reports 5 cases of prothrombotic immune thrombocytopenia following vaccination with AZD1222. Patients presented with various clinical manifestations, including thrombocytopenia and elevated D-dimer levels. Treatment experience suggests that anticoagulation may be effective, but there is also a risk of unusual and severe thromboembolic events.

BLOOD (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Hematology

Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination

Sean Platton et al.

Summary: Commercially available assays in the UK showed poor sensitivity for detecting anti-PF4 antibodies in suspected VITT patients when compared to ELISA testing. No superiority of IgG-ELISAs over polyspecific ELISAs in sensitivity to VITT was demonstrated, and no single ELISA method detected all possible/probable VITT cases. If a single ELISA test is negative, a second ELISA or platelet activation assay should be considered for cases with strong clinical suspicion.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia

Caroline Vayne et al.

Summary: VITT, a rare vaccine-induced disorder, may not be detected by rapid assays for anti-PF4 antibodies used to diagnose HIT. The PF4-serotonin release assay is effective in detecting IgG antibodies to PF4-PVS associated with VITT.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021

David K. Shay et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021

Jessica R. MacNeil et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Medicine, General & Internal

Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine

Swathi Sangli et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia

Angela Huynh et al.

Summary: Alanine-scanning mutagenesis is used to identify the PF4 epitope that is recognized by anti-PF4 antibodies in patients with vaccine-induced immune thrombotic thrombocytopaenia, revealing that the epitope corresponds to the heparin-binding site on PF4. VITT anti-PF4 antibodies show stronger binding response compared to HIT anti-PF4 antibodies, potentially contributing to platelet activation and thrombosis by mimicking the effect of heparin binding on PF4. The findings suggest a potential mechanism for VITT development related to immune complexes formation and platelet activation via Fc gamma receptor IIa.

NATURE (2021)

Add to Collection

Editorial Material Clinical Neurology

Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery A Case Report

Uwe Walter et al.

Summary: Vaccine-induced isolated carotid arterial thrombosis occurred in a 31-year-old male after receiving the AstraZeneca COVID-19 vaccine. Treatment led to symptom improvement and the importance of vaccine history in evaluating both venous and arterial thromboembolic events was highlighted.

NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Sue Pavord et al.

Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Vaccine-Induced Thrombocytopenia with Severe Headache

Farid Salih et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

Alex Bourguignon et al.

Summary: High-dose intravenous immune globulin (IVIG) combined with anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), showing a good response in reducing antibody-induced platelet activation, particularly in cases of VITT induced by ChAdOx1 nCoV-19 vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

Hannah G. Rosenblum et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Medicine, General & Internal

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

Alex Bourguignon et al.

Summary: The use of high-dose IVIG plus anticoagulation is recommended for the treatment of VITT, a rare side effect of adenoviral vector vaccines against Covid-19. Response to IVIG therapy in VITT patients showed reduced platelet activation and improvement in symptoms.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Hematology

Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia

Kamal K. Sahu et al.

JOURNAL OF BLOOD MEDICINE (2020)

Add to Collection

Article Computer Science, Interdisciplinary Applications

The REDCap consortium: Building an international community of software platform partners

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2019)

Add to Collection

Article Obstetrics & Gynecology

Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis

Joann V. Pinkerton et al.

CLINICAL OBSTETRICS AND GYNECOLOGY (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

A Test in Context: D-Dimer

Jeffrey I. Weitz et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

Add to Collection

Review Hematology

Environmental and Genetic Risk Factors Associated with Venous Thromboembolism

Marta Crous-Bou et al.

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)

Add to Collection

Review Immunology

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

Tom T. Shimabukuro et al.

VACCINE (2015)

Add to Collection

Article Hematology

Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder

Theodore E. Warkentin et al.

BLOOD (2014)

Add to Collection

Review Hematology

Risk factors for venous thrombosis - current understanding from an epidemiological point of view

Willem M. Lijfering et al.

BRITISH JOURNAL OF HAEMATOLOGY (2010)

Add to Collection

Article Computer Science, Interdisciplinary Applications

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.